Evaluation of the Osteoinductivity of Atorvastatin Combined With β-TCP

NCT ID: NCT06382974

Last Updated: 2024-08-13

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-31
• Study Completion Date: 2026-03-31

Brief Summary

This case series study aims to evaluate the local effects of Atorvastatin (which belongs to the family of lipid-lowering drugs, known as statins) combined with β-TCP (which is a synthetic osteoconductive bone graft), on the volume of the residual bone defects and on hastening the bone regeneration after radicular jaw cyst enucleation using CBCT-based volumetric analysis to calculate the shrinkage rate of these defects.

Detailed Description

Statement of the problem:

According to the literature, the residual bone defects after medium-large-sized jaw cyst enucleation pose the risk for infection, insufficient healing, and pathological fracture. the gold standard of bone grafting materials remains the autologous bone graft, yet it is accompanied by risks including second surgery, the morbidity of the donor site, excessive bleeding, etc.

Therefore, there is a constant search for alternative bone grafting materials, this is where the addition of atorvastatin to an osteoconductive synthetic bone grafting material (β-TCP) comes in. β-TCP takes anywhere from 6 to 18 months for complete resorption and replacement by bone, according to the literature.

The addition of an osteoinductive material to an osteoconductive grafting material like β-TCP holds two premises; increasing the resorption of the β-TCP particles at the expense of bone deposition, and therefore leads to hastening the bone generation of the residual bone defects.

Rationale:

Studies have shown that the local application of lipid-lowering drugs, statins, induces bone growth by stimulating BMP-2. therefore, the addition of these pharmacological agents to osteoconductive bone graft materials, which lack osteogenic properties, could be a promising approach for bone regeneration.

However, there is still no consensus in the literature on the optimal therapeutic dose and mode of application for statins. Furthermore, limited studies are available in the literature regarding the use of statins especially Atorvastatin as a biological modifier in filling bone defects after cyst enucleation.

Therefore, the purpose of this study is to validate and evaluate the osteoinductivity of statins+ β-TCP combination using the Gouda et al., methodology used in maxillary sinus lifting using simvastatin but instead using atorvastatin in filling the residual defects of medium-large odontogenic radicular cysts (1.5 - 4 cm), which shows the suppressive influence on bone formation, as well as a greater risk for pathological fracture, infection, and insufficient bone healing.

Methodology:

The ratio of atorvastatin to β-TCP will be 0.1 mg: 14 mg, which was the methodology adopted by Gouda et al, based on the methodology of Nyan et al.

Conditions

Infection; Bone Loss

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

bone grafting using atorvastatin combined with beta-TCP

the 10 volunteers will undergo cyst enucleation followed by filling the residual bone defects with atorvastatin combined with beta-TCP in the ratio of 0.1 mg: 14 mg.

Group Type: EXPERIMENTAL

Cyst enucleation and bone grafting

Intervention Type: PROCEDURE

cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.

Interventions

Cyst enucleation and bone grafting

cyst enucleation followed by bone grafting the residual bone defects using Atorvastatin combined with β-TCP.

Intervention Type: PROCEDURE

Other Intervention Names

Bone grafting

Eligibility Criteria

Inclusion Criteria

1. Male and female patients

2. Patients 18 to 40 years old

3. Radicular cyst with a maximum diameter from 1.5 to 4.0 cm;

4. Focal teeth were preserved with root canal treatment;

5. No previous surgical treatment of the cyst site;

6. No evidence of acute inflammation;

7. In good physical status and oral health;

8. Regular attendance at control visits

Exclusion Criteria

1. Patients < 17 years old

2. Radicular cyst with a maximum diameter < 1.5 cm.

3. Pregnancy or lactation

4. Aggregate systemic pathologies such as diabetes, thyroid disorders, and bone metabolism diseases, among others;

5. Patients taking calcium, bisphosphonates, glucocorticoids, or other drugs that can interfere with the metabolism of bone;

6. Patients with uncontrolled periodontal conditions, endodontic conditions, and other oral disorders;

7. Heavy smokers (10 cigarettes/day or more)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cairo University

OTHER

Sponsor Role: lead

Responsible Party

Yara Gamal Mohamed Mahmoud

post-graduate master student

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Salah Yassin

Role: STUDY_DIRECTOR

department of oral and maxillofacial surgery, cairo university

Locations

Cairo University

Cairo, , Egypt

Countries

Egypt

Central Contacts

Yara Mahmoud

Role: CONTACT

yara.mahmoud@dentistry.cu.edu.eg

01100764737

Mohamed Mosa

Role: CONTACT

mohamed.mosa@dentistry.cu.edu.eg

Facility Contacts

Role: primary

surgery@dentistry.cu.edu.eg

23634965

Related Links

https://pubmed.ncbi.nlm.nih.gov/19397639/

first in-vivo study to test the methodology adopted in this research

https://pubmed.ncbi.nlm.nih.gov/28952824/

the clinical study methodology adopted in this research

Other Identifiers

3-3-14

Identifier Type: -

Identifier Source: org_study_id